AraCd

araCd, also known as Cytarabine Arabinoside or Cytosine Arabinoside, is a synthetic nucleoside analog of deoxycytidine. It is a chemotherapy drug that functions as an antimetabolite. AraCd is primarily used in the treatment of various leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Its mechanism of action involves incorporation into DNA and RNA, where it inhibits DNA synthesis and induces DNA damage, ultimately leading to cancer cell death. AraCd is administered intravenously or intrathecally. Common side effects can include myelosuppression (low blood cell counts), nausea, vomiting, diarrhea, and hair loss. It is important to note that araCd can also cause neurological side effects. The drug's efficacy and toxicity necessitate careful monitoring by healthcare professionals. Its development and application have significantly impacted the management of hematological malignancies.